Description:
Zilebesiran Cardiovascular Outcomes Trial-Seamless Phase 3 design with BP sub study analysis to de risk CVOT
Aim/objective:
To evaluate whether zilebesiran versus placebo reduces the risk of CV death, non-fatal MI, nonfatal stroke or HF events .
Sample size: 1000
Updated on Oct 2025